

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10541683
Filing Date	2006-04-07
First Named Inventor	Frieder SCHWENK
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	100725-49 (40) KGB

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
			<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10541683
	Filing Date		2006-04-07
	First Named Inventor		Frieder SCHWENK
	Art Unit		1632
	Examiner Name		Michael C. Wilson
	Attorney Docket Number		100725-49 (40) KGB

	1	FUKUSHIGE, et al; "Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells" Proc. Nati. Acad. Sci. USA, Vol. 89, pp. 7905-7909, September 1992, Genetics	<input type="checkbox"/>
	2	LI, et al, "RXRa ablation in skin keratinocytes results in alopecia and epidermal alterations"; Development 128, 675-688 (2001) 675-688, Printed in Great Britain © The Company of Biologists Limited 2001	<input type="checkbox"/>
	3	McBURNEY, et al, "Murine PGK-1 Promoter Drives Widespread But Not Uniform Expression in Transgenic Mice"; DEVELOPMENTAL DYNAMICS (1994), 278-293, WILEY-LISS, INC.	<input type="checkbox"/>
	4	Okabe et al; "Green mice' as a source of ubiquitous green cells"; FEBS Letters 407 (1997) 313^31	<input type="checkbox"/>
	5	ORBAN et al; "Tissue- and site-specific DNA recombination in transgenic mice"; Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 6861-6865, August 1992, Genetics	<input type="checkbox"/>
	6	Ovchinnikov et al; "Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice"; Genesis. 2000 Feb;26(2):145-6.	<input type="checkbox"/>
	7	Postic et al; "DNA Excision in Liver by an Albumin-Cre Transgene Occurs Progressively With Age"; genesis 26:149-150 (2000), 2000 Wiley-Liss, Inc.	<input type="checkbox"/>
	8	Ray MK, et al; "Development of a transgenic mouse model using rat insulin promoter to drive the expression of CRE recombinase in a tissuespecific manner."; Int J Pancreatol. 1999 Jun;25(3):157-63.	<input type="checkbox"/>
	9	Rickert et al; "B lymphocyte-specific, Cre-mediated mutagenesis in mice", Nucleic Acids Research, 1997, Vol. 25, No. 6 1317-1318, 1997 Oxford University Press	<input type="checkbox"/>
	10	Saam, et al; "Inducible Gene Knockouts in the Small Intestinal and Colonic Epithelium", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 53, Issue of December 31, pp. 38071-38082, 1999,	<input type="checkbox"/>
	11	Schlake et al; "Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci.", Biochemistry. 1994 Nov 1;33(43):12746-51.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10541683
	Filing Date	2006-04-07
	First Named Inventor	Frieder SCHWENK
	Art Unit	1632
	Examiner Name	Michael C. Wilson
	Attorney Docket Number	100725-49 (40) KGB

	12	Torres et al; "Labotatory Protocols for Conditional Gene Targeting", Oxford University Press 1997	<input type="checkbox"/>
	13	Tsien, et al; "Subregion- and Cell Type–Restricted Gene Knockout in Mouse Brain"; Cell, Vol. 87, 1317–1326, December 27, 1996, Copyright ©1996 by Cell Press	<input type="checkbox"/>
	14	Urlinger, et al; "Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity"; PNAS July 5, 2000 vol. 97 no. 14 7963–7968	<input type="checkbox"/>
	15	Utomo, et al; "Temporal, spatial, and cell type–specific control of Cre-mediated DNA recombination in transgenic mice" 1999 Nature America Inc. • http://biotech.nature.com , NATURE BIOTECHNOLOGY VOL 17 NOVEMBER 1999	<input type="checkbox"/>
	16	Yao, et al; "A Novel Tetracycline-Inducible Viral Replication Switch"	<input type="checkbox"/>
	17	Agah, et al; Gene Recombination in Postmitotic Cells, "Targeted Expression of Cre Recombinase Provokes Cardiac-restricted, Site-specific Rearrangement in Adult Ventricular Muscle In Vivo"; J. Clin. Invest. © The American Society for Clinical Investigation, Inc., Volume 100, Number 1, July 1997, 169–179	<input type="checkbox"/>
	18	Barlow, et al; Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments"; Nucleic Acids Research, 1997, Vol. 25, No. 12 2543–2545	<input type="checkbox"/>
	19	Brünin, et al; "A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the Metabolic Syndrome of NIDDM without Altering Glucose Tolerance"; Molecular Cell, Vol. 2, 559–569, November, 1998, Copyright 1998 by Cell Press	<input type="checkbox"/>
	20	Chung, et al; "Analysis of Different Promoter Systems for Efficient Transgene Expression in Mouse Embryonic Stem Cell Lines"; Stem Cells. 2002 ; 20(2): 139–145.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Michael Wilson/	Date Considered	08/30/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10541683
	Filing Date	2006-04-07
	First Named Inventor	Frieder SCHWENK
	Art Unit	1632
	Examiner Name	Michael C. Wilson
	Attorney Docket Number	100725-49 (40) KGB

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.